PCVaxcyte PCVX · NASDAQ
$63.68 +0.09% (+$0.06)
- Market cap
- $9.76B
- Enterprise value
- $9.69B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -40.6%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.23
- Free float
- 89.4%
About the company
Vaxcyte is an American biotechnology company focused on developing vaccines for the prevention of serious infectious diseases. The company specializes in advanced vaccine technologies, including cellular therapies and protein-based vaccines, with the aim of providing effective protection against pathogens that currently lack sufficient vaccines. Vaxcyte is developing vaccines for infections such as pneumococcal disease and is working to improve immunization and the prevention of infectious diseases globally.
Sector
Healthcare
Industry
Biotechnology
CEO
Grant E. Pickering
Employees
507
Headquarters
San Carlos
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number